HUP0203241A2 - Heterotrimer G-fehérje jelátvitel inhibitor és egy rákellenes hatóanyag-kombináció alkalmazása rákbetegség gyógyítására - Google Patents

Heterotrimer G-fehérje jelátvitel inhibitor és egy rákellenes hatóanyag-kombináció alkalmazása rákbetegség gyógyítására

Info

Publication number
HUP0203241A2
HUP0203241A2 HU0203241A HUP0203241A HUP0203241A2 HU P0203241 A2 HUP0203241 A2 HU P0203241A2 HU 0203241 A HU0203241 A HU 0203241A HU P0203241 A HUP0203241 A HU P0203241A HU P0203241 A2 HUP0203241 A2 HU P0203241A2
Authority
HU
Hungary
Prior art keywords
combination
cancer
protein signals
heterotrimeric protein
cancer treatment
Prior art date
Application number
HU0203241A
Other languages
English (en)
Inventor
Thomas Gordon
Marie-Odile Lonchampt
Barry Morgan
Grégoire Prevost
Original Assignee
Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9914037A external-priority patent/FR2800616B1/fr
Priority claimed from FR0000104A external-priority patent/FR2803524B1/fr
Application filed by Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) filed Critical Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)
Publication of HUP0203241A2 publication Critical patent/HUP0203241A2/hu
Publication of HUP0203241A3 publication Critical patent/HUP0203241A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely heterotrimer G fehérjékjelátvitelének legalább egy inhibitorát és legalább egy rákelleneshatóanyagot tartalmaz az alábbiak közül: preniltranszferázinhibitorok, taxol és analógjai, gemcitabin és kamptotecin vagyanalógjai, terápiás alkalmazásra párhuzamosan, külön-külön vagy egyadott időtartam alatt elosztva rákbetegség gyógyításra. Ó
HU0203241A 1999-11-09 2000-11-08 Combination of product inhibiting transduction of g heterotrimeric protein signals and anti-cancer agent for use in cancer treatment HUP0203241A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9914037A FR2800616B1 (fr) 1999-11-09 1999-11-09 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR0000104A FR2803524B1 (fr) 2000-01-06 2000-01-06 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
PCT/FR2000/003098 WO2001034203A1 (fr) 1999-11-09 2000-11-08 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer

Publications (2)

Publication Number Publication Date
HUP0203241A2 true HUP0203241A2 (hu) 2003-02-28
HUP0203241A3 HUP0203241A3 (en) 2006-07-28

Family

ID=26212071

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203241A HUP0203241A3 (en) 1999-11-09 2000-11-08 Combination of product inhibiting transduction of g heterotrimeric protein signals and anti-cancer agent for use in cancer treatment

Country Status (15)

Country Link
US (3) US7034024B1 (hu)
EP (2) EP1430934A1 (hu)
JP (1) JP2003513940A (hu)
AT (1) ATE284224T1 (hu)
AU (1) AU1400401A (hu)
CA (1) CA2390317C (hu)
CZ (1) CZ20021550A3 (hu)
DE (1) DE60016625T2 (hu)
DK (1) DK1233787T3 (hu)
ES (1) ES2234692T3 (hu)
HU (1) HUP0203241A3 (hu)
PL (1) PL204716B1 (hu)
PT (1) PT1233787E (hu)
RU (1) RU2298417C2 (hu)
WO (1) WO2001034203A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
KR100594353B1 (ko) * 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
DE102009033392A1 (de) * 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
MX368615B (es) * 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN106317057B (zh) * 2015-07-02 2019-02-01 北京桦冠医药科技有限公司 具有咪唑并吡嗪类衍生物，其制备及其在医药上的应用
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
AU2018260414A1 (en) 2017-04-24 2019-10-17 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0517353A (ja) * 1991-07-10 1993-01-26 Kanebo Ltd 制癌作用増強剤
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0865440B1 (en) * 1995-12-08 2002-04-03 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
HUP0102473A3 (en) * 1997-12-22 2003-07-28 Schering Corp Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase

Also Published As

Publication number Publication date
CA2390317A1 (fr) 2001-05-17
EP1233787A1 (fr) 2002-08-28
PT1233787E (pt) 2005-04-29
ES2234692T3 (es) 2005-07-01
JP2003513940A (ja) 2003-04-15
DE60016625D1 (de) 2005-01-13
EP1430934A1 (fr) 2004-06-23
AU1400401A (en) 2001-06-06
EP1233787B8 (fr) 2005-05-18
RU2298417C2 (ru) 2007-05-10
RU2002115262A (ru) 2004-01-27
DK1233787T3 (da) 2005-08-15
US7034024B1 (en) 2006-04-25
PL204716B1 (pl) 2010-02-26
ATE284224T1 (de) 2004-12-15
CA2390317C (fr) 2010-03-23
DE60016625T2 (de) 2005-12-22
PL356028A1 (en) 2004-06-14
EP1233787B1 (fr) 2004-12-08
US20060074078A1 (en) 2006-04-06
HUP0203241A3 (en) 2006-07-28
US20090270341A1 (en) 2009-10-29
WO2001034203A1 (fr) 2001-05-17
CZ20021550A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
HUP0203241A2 (hu) Heterotrimer G-fehérje jelátvitel inhibitor és egy rákellenes hatóanyag-kombináció alkalmazása rákbetegség gyógyítására
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
TR200201067T2 (tr) Bir tramadol maddesi ve bir antikonvülsan ilaç içeren bileşimler
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
NO20011502D0 (no) Fentanylsammensetning for behandling av akutt smerte
ATE520668T1 (de) Sigmarezeptor-inhibitoren
HUP0203556A2 (hu) Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
HUP0301346A2 (hu) Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
HUP0001632A2 (hu) Szelektív foszfodiészteráz PDE enzim inhibitort tartalmazó gyógyszerkészítmények
IL156827A0 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
BR0014598A (pt) Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
PL368737A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
HUP0303589A2 (hu) Egy taxán és egy ciklin-dependens kináz inhibitor kombinációja

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: IPSEN PHARMA S.A.S., FR

Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.), FR

FD9A Lapse of provisional protection due to non-payment of fees